BR112018001942A2 - ?novo uso de sulfato de dextrano? - Google Patents

?novo uso de sulfato de dextrano?

Info

Publication number
BR112018001942A2
BR112018001942A2 BR112018001942A BR112018001942A BR112018001942A2 BR 112018001942 A2 BR112018001942 A2 BR 112018001942A2 BR 112018001942 A BR112018001942 A BR 112018001942A BR 112018001942 A BR112018001942 A BR 112018001942A BR 112018001942 A2 BR112018001942 A2 BR 112018001942A2
Authority
BR
Brazil
Prior art keywords
dextran sulfate
new use
inhibiting
treating
subject
Prior art date
Application number
BR112018001942A
Other languages
English (en)
Portuguese (pt)
Inventor
Bruce Adam
Waas Anders
Bruce Lars
Original Assignee
Tx Medic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tx Medic Ab filed Critical Tx Medic Ab
Publication of BR112018001942A2 publication Critical patent/BR112018001942A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/02—Dextran; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR112018001942A 2015-07-30 2016-07-15 ?novo uso de sulfato de dextrano? BR112018001942A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1551050A SE539575C2 (en) 2015-07-30 2015-07-30 Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
PCT/SE2016/050720 WO2017018922A1 (en) 2015-07-30 2016-07-15 New use of dextran sulfate

Publications (1)

Publication Number Publication Date
BR112018001942A2 true BR112018001942A2 (pt) 2018-09-18

Family

ID=57884849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001942A BR112018001942A2 (pt) 2015-07-30 2016-07-15 ?novo uso de sulfato de dextrano?

Country Status (11)

Country Link
US (1) US10478451B2 (https=)
EP (1) EP3328395B1 (https=)
JP (1) JP6837679B2 (https=)
CN (2) CN114712385A (https=)
BR (1) BR112018001942A2 (https=)
DK (1) DK3328395T3 (https=)
EA (1) EA034313B1 (https=)
ES (1) ES2882115T3 (https=)
HK (1) HK1246640A1 (https=)
SE (1) SE539575C2 (https=)
WO (1) WO2017018922A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018212708A1 (en) * 2017-05-17 2018-11-22 Tx Medic Ab Treatment of glaucoma
ES2777836T3 (es) * 2017-05-17 2020-08-06 Tx Medic Ab Tratamiento del glaucoma
AU2018329430B2 (en) 2017-09-08 2024-05-02 Tx Medic Ab New use of dextran sulfate
US20190275212A1 (en) * 2018-03-09 2019-09-12 Carmeda Ab Processes for immobilising biological entities
SE543275C2 (en) * 2019-03-07 2020-11-10 Tx Medic Ab Treatment efficiency evaluation
SE544447C2 (en) * 2020-09-29 2022-05-31 Tx Medic Ab Treatment of fatty liver diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
EP0868191A1 (en) 1995-12-18 1998-10-07 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
US20040224922A1 (en) 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
SE525461C3 (sv) * 2002-11-28 2005-03-23 Prophymed Ab Ny användning av dextransulfat
WO2007028053A2 (en) * 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
WO2007075388A2 (en) * 2005-12-15 2007-07-05 X-Cell Medical Incorporated Methods of locally treating and preventing cardiac disorders
WO2008134430A1 (en) * 2007-04-24 2008-11-06 Novelmed Therapeutics Inc. Methods and compositions of inhibiting complement and cellular activation with dextran sulfate
WO2011091167A2 (en) * 2010-01-22 2011-07-28 The General Hospital Corporation Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
WO2013057167A1 (en) * 2011-10-18 2013-04-25 Csl Behring Gmbh Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
CN102973593A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗肝纤维化药物中的应用
JP6557683B2 (ja) * 2014-06-12 2019-08-07 ティーエックス メディック エービー 被験体において血管新生を誘導するための１００００ｄａ未満の平均分子量を有するデキストラン硫酸の使用
WO2015190989A1 (en) * 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject

Also Published As

Publication number Publication date
US20180221403A1 (en) 2018-08-09
US10478451B2 (en) 2019-11-19
CN107921055A (zh) 2018-04-17
DK3328395T3 (da) 2021-08-09
JP6837679B2 (ja) 2021-03-03
SE539575C2 (en) 2017-10-17
HK1246640A1 (zh) 2018-09-14
SE1551050A1 (en) 2017-01-31
EP3328395A1 (en) 2018-06-06
CN114712385A (zh) 2022-07-08
ES2882115T3 (es) 2021-12-01
EA034313B1 (ru) 2020-01-28
WO2017018922A1 (en) 2017-02-02
EA201890212A1 (ru) 2018-06-29
EP3328395B1 (en) 2021-06-09
EP3328395A4 (en) 2018-06-20
JP2018521086A (ja) 2018-08-02

Similar Documents

Publication Publication Date Title
HUE054690T2 (hu) 8-Oxetán-3-il-3,8-diazabiciklo[3.2.1]oktán-3-il-csoporttal szubsztituált vegyületek HIV inhibitorokként
BR112016008541A2 (pt) composições úteis para tratar distúrbios relacionados a kit
WO2017132580A3 (en) Split inteins with exceptional splicing activity
DK3513809T3 (da) Medicinsk sammensætning, som omfatter tivozanib
EA201691194A1 (ru) Стимуляторы ргц
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX380512B (es) Formulación de revestimiento para madera.
BR112018001942A2 (pt) ?novo uso de sulfato de dextrano?
BR112016017564A8 (pt) métodos e composições para matar células senescentes e para tratar doenças e transtornos associados à senescência
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
BR112016006613A2 (pt) métodos para produção, estabilização e uso de blastosporos fúngicos
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
MX2017001553A (es) Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2015002897A1 (es) Inhibidores de bace1
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
WO2015077657A3 (en) Stat3 inhibitors and uses thereof
SG11201908281VA (en) Phenalene-1-one-containing photosensitizer composition, phenalene-1-one compound and the use thereof
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
WO2015200534A3 (en) Small molecule agonists of neurotensin receptor 1
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
CL2019001804A1 (es) Activador de nrf2.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]